Abstract: This invention relates to human medicine, and particularly with a pharmaceutical combination made up with Epidermal Growth Factor (EGF) and a Growth Hormone secretagogue hexapeptide (GHRP); being useful to prevent tissue damages due to blood flow suppression as to enhance tissue repair following ischaemic damages. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is useful to promote cellular survival when tissues or organs are exposed to prolonged ischaemic periods.